The evaluation of complement inhibition therapy in geographic atrophy highlights the potential benefits and ongoing concerns regarding efficacy, safety, and regulatory decisions, researchers wrote in a Viewpoint article. Pegcetacoplan and avacincaptad pegol have shown promise in slowing disease progression. However, uncertainties remain about their functional benefits and long-term risks. Phase III trials demonstrated a reduction in geographic atrophy lesion growth, but methodological concerns and risks associated with frequent intravitreal injections persist. Despite the promising data, concerns also exist regarding regulatory approvals and clinical adoption. The lack of measurable functional improvement in current therapies is a key limitation. Moving forward, the researchers suggested, investigations should explore alternative therapeutic targets beyond complement inhibition.

Source: JAMA Ophthalmology